newsfilter
← Latest News
PR Newswire·

Synaptogenix Moves Forward with Clinical Development Plans for Bryostatin-1 as a Treatment for Multiple Sclerosis

NEW YORK, Feb. 23, 2022 /PRNewswire/ -- Synaptogenix, Inc. (NASDAQ:SNPX), a clinical-stage biopharmaceutical company developing regenerative therapeutics for neurodegenerative disorders, today announced plans to develop Bryostatin-1 for the treatment of